GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis  

作　　者：Anmol Singh Aalam Sohal Akash Batta 

机构地区：[1]Department of Medicine,Tristar Centennial Medical Center,Nashville,TN 37203,United States [2]Division of Gastroenterology,Creighton University School of Medicine,Phoenix,AZ 85012,United States [3]Department of Cardiology,Dayanand Medical College and Hospital,Ludhiana 141001,Punjab,India

出　　处：《World Journal of Gastroenterology》2024年第48期5205-5211,共7页世界胃肠病学杂志（英文）

摘　　要：The global prevalence of metabolic dysfunction-associated steatotic liver disease(MASLD)is estimated at 32.4%,reflecting its growing clinical significance.MASLD,which includes MASLD and metabolic dysfunction-associated steato-hepatitis(MASH)has been linked to increased metabolic,cardiovascular,and malignant morbidity.Progression into fibrotic stages of MASLD is also strongly associated with liver-related mortality.The past few years have seen a heightened focus on creating innovative therapeutic strategies for MASH management.GLP-1 receptor agonists(RA)have also emerged as a potential treatment option.Studies on GLP-1 agonists,such as liraglutide and semaglutide,have demonstrated efficacy in MASH management,albeit with limited histological improvement of fibrosis.However,recent investigations into GLP-1/GIP RA(tirzepatide)and Glucagon/GLP-1 RA(survodutide)have shown even more encouraging results,with higher rates of MASH resolution and fibrosis improvement.The tolerability of these medications due to their gastrointestinal side effects remains a major concern.Future research should focus on optimizing drug regimens,identifying patients most likely to benefit,and balancing efficacy with tolerability.The evolving landscape of MASH therapeutics suggests a bright future,with the potential for combination therapies to further enhance patient outcomes.

关 键 词：Glucagon-like peptide-1 receptor agonists Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis Liver fibrosis Semaglutide Tirzepatide Survodutide 

分 类 号：R285.5[医药卫生—中药学]